Peter Robert Galle, Bruno Sangro, Thomas Decaens, Masatoshi Kudo, ShuKui Qin, Leonardo Da Fonseca, Hatim Karachiwala, Joong-Won Park, Edward Gane, Matthias Pinter, David Tai, Armando Santoro, Gonzalo Pizarro, Michael Schenker, Qi Wang, Maria Jesus Jimenez Exposito, Thomas Yau. "Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): 4-year follow-up of CheckMate 9DW.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.2_suppl.lba479